Abstract
The effectiveness of the developed combined drug as capsule and suspension dosage forms based on dimephosphone® (dimethyl 1,1-dimethyl-3-oxobutylphosphonate) and calcium carbonate was demonstrated for treatment and prophylaxis of bone diseases. According to IR spectra, dimephosphone® was chemisorbed to calcium ions on the surface of calcium carbonate to form surface calcium phosphonates. Dimephosphone® adsorption (A) as a function of its concentration (C) in aqueous solutions obeyed formally the Langmuir equation. The remodeling action for bone tissue by the suspension dosage form was verified using a glucocorticoid-induced osteoporosis model in rats.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
